|
Status |
Public on Jan 01, 2018 |
Title |
A375_LTM_8h_s3 |
Sample type |
RNA |
|
|
Source name |
Human A375 melanoma cell line
|
Organism |
Homo sapiens |
Characteristics |
cell line: A375 treatment: lactimidomycin time: 8 h
|
Treatment protocol |
A375 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.
|
Growth protocol |
A375 cell lines was maintained in humidified air/5% CO2 in RPMI 1640 medium with 5% fetal bovine serum and antibiotics, and passaged by trypsinization.
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was isolated by using TRIzol reagent (life Technologies), then further purified using the RNeasy plus Mini kit (Qiagen).
|
Label |
biotin
|
Label protocol |
300 ng total RNA was amplified and biotin-labeled through a Eberwine procedure using Illumina TotalPrep RNA Amplification kits (Ambion).
|
|
|
Hybridization protocol |
As per Illumina instructions, with detection by Streptavidin-Cy3 conjugate.
|
Scan protocol |
As per instructions for Illumina BeadArray Reader
|
Data processing |
The non-normalized data were generated by GenomeStudio with background correction. The normalized data were generated from bead-level data by methods previously described (PMID: 20805315). In brief, bead-level values were quantile-normalized, adjusted by a model-based background correction method (PMID: 18450815), trimmed by the 3-MAD method employed by Illumina, and then averaged to give a single probe-level value.
|
|
|
Submission date |
Jul 08, 2014 |
Last update date |
Jan 01, 2018 |
Contact name |
Wencai Ma |
Organization name |
MD Anderson Cancer Center
|
Street address |
7455 Fannin st
|
City |
Houston |
ZIP/Postal code |
77054 |
Country |
USA |
|
|
Platform ID |
GPL10558 |
Series (2) |
GSE59183 |
Human A375 melanoma cell line treated with trifluorothymidine (TFT) and lactimidomycin (LTM) |
GSE59409 |
Correlating Gene Signatures with Outcome to find Features and Drugs Relevant to Cancer |
|